Association between the rs342293 polymorphism and adverse cardiac events in patients undergoing percutaneous coronary intervention

Summary

The single nucleotide polymorphism (SNP) rs342293 has been shown to influence platelet number and mean platelet volume (MPV). We investigated the association between the rs342293 polymorphism and cardiovascular outcome in a prospective cohort study. The rs342293 polymorphism was analysed in 404 patients with coronary artery disease undergoing percutaneous coronary intervention. The rates of cardiac adverse events were recorded during two years of follow-up. The polymorphism was associated with MPV (median 10.1 fL, interquartile range [IQR]: 9.6 to 10.6 in patients with the CC-allele vs 10.4 fL, IQR: 9.9 to 11.1 in G>C SNP carriers; p<0.001), but not with platelet count. Survival analysis indicated that carriers of the rs342293 G variant had a substantially higher risk to develop cardiac adverse events compared with wild type carriers during two years of follow-up (33% vs 22%; adjusted hazard ratio = 1.63, 95% confidence interval = 1.06–2.52, p=0.027). The rs342293 SNP could explain 2.9% of the variability in MPV (p=0.01). In conclusion, patients undergoing coronary stenting who carry the G-variant of the rs342293 SNP which is associated with larger MPV are at higher risk for adverse cardiovascular outcome.

Keywords

Platelet aggregation - polymorphism - genetic - outcome assessment (healthcare) - platelet count - myocardial Infarction

• References

• 1 Eisen A, Bental T, Assali A. et al. Mean platelet volume as a predictor for longterm outcome after percutaneous coronary intervention. J Thromb Thrombolysis 2013; 36: 469-474.
• 2 Shah B, Oberweis B, Tummala L. et al. Mean platelet volume and long-term mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol 2013; 111: 185-189.
• 3 Paulus JM. Platelet size in man. Blood 1975; 46: 321-336.
• 4 Marin V, Montero-Julian FA, Gres S. et al. The IL-6-soluble IL-6Ralpha autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J Immunol 2001; 167: 3435-3442.
• 5 Martin JF, Kristensen SD, Mathur A. et al. The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. Nature Rev Cardiol 2012; 09: 658-670.
• 6 Boos CJ, Lip GY. Assessment of mean platelet volume in coronary artery disease - what does it mean?. Thromb Res 2007; 120: 11-13.
• 7 Mayer FJ, Hoke M, Schillinger M. et al. Mean platelet volume predicts outcome in patients with asymptomatic carotid artery disease. Eur J Clin Invest. 2013 Epub ahead of print.
• 8 Varol E, Uysal BA, Ersoy I. et al. Mean platelet volume, an indicator of platelet reactivity, is increased in patients with patent foramen ovale. Blood Coagul Fibrinolysis 2013; 24: 605-607.
• 9 Goncalves SC, Labinaz M, Le May M. et al. Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. Am J Cardiol 2011; 107: 204-209.
• 10 Soranzo N, Rendon A, Gieger C. et al. A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood 2009; 113: 3831-3837.
• 11 Mahaney MC, Brugnara C, Lease LR. et al. Genetic influences on peripheral blood cell counts: a study in baboons. Blood 2005; 106: 1210-1214.
• 12 Evans DM, Frazer IH, Martin NG. Genetic and environmental causes of variation in basal levels of blood cells. Twin Res 1999; 02: 250-257.
• 13 Siller-Matula JM, Delle-Karth G, Christ G. et al. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol 2013; 167: 430-435.
• 14 Siller-Matula JM, Tentzeris I, Vogel B. et al. Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points. Clin Res Cardiol 2010; 99: 645-650.
• 15 Zimarino M, Corazzini A, Ricci F. et al. Late thrombosis after double versus single drugeluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies. JACC Cardiovasc Interv 2013; 06: 687-695.
• 16 Zimarino M, Renda G, De Caterina R. Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents. Drugs 2005; 65: 725-732.
• 17 Christ G, Hafner T, Siller-Matula JM. et al. Platelet Inhibition by Abciximab Bolus-Only Administration and Oral ADP Receptor Antagonist Loading in Acute Coronary Syndrome Patients: The Blocking and Bridging Strategy. Thromb Res 2013; 132: e36-e41.
• 18 Chu SG, Becker RC, Berger PB. et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 08: 148-156.
• 19 Siller-Matula JM, Delle-Karth G, Lang IM. et al. Phenotyping vs genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost 2012; 10: 529-542.
• 20 Hawkins PT, Stephens LR. PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis. Science 2007; 318: 64-66.
• 21 Boersma HH, Kietselaer BL, Stolk LM. et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005; 46: 2035-2050.
• 22 Rand ML, Wang H, Pluthero FG. et al. Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of plateletmediated events during thrombus formation. J Thromb Haemost 2012; 10: 1109-1119.
• 23 Meisinger C, Prokisch H, Gieger C. et al. A genome-wide association study identifies three loci associated with mean platelet volume. Am J Human Gen 2009; 84: 66-71.
• 24 Neer EJ, Schmidt CJ, Nambudripad R. et al. The ancient regulatory-protein family of WD-repeat proteins. Nature 1994; 371: 297-300.
• 25 Arthur WT, Ellerbroek SM, Der CJ. et al. XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC. J Biol Chem 2002; 277: 42964-42972.
• 26 Draviam VM, Stegmeier F, Nalepa G. et al. A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nature Cell Biol 2007; 09: 556-564.
• 27 Gieger C, Radhakrishnan A, Cvejic A. et al. New gene functions in megakaryo-poiesis and platelet formation. Nature 2011; 480: 201-208.
• 28 de Gaetano G, Santimone I, Gianfagna F. et al. Variability of platelet indices and function: acquired and genetic factors. Handbook of Experimental Pharmacology 2012; 395-434.
• 29 Martin JF, Plumb J, Kilbey RS. et al. Changes in volume and density of platelets in myocardial infarction. Br Med J 1983; 287: 456-459.
• 30 Kishk YT, Trowbridge EA, Martin JF. Platelet volume subpopulations in acute myocardial infarction: an investigation of their homogeneity for smoking, infarct size and site. Clin Sci 1985; 68: 419-425.
• 31 Senaran H, Ileri M, Altinbas A. et al. Thrombopoietin and mean platelet volume in coronary artery disease. Clin Cardiol 2001; 24: 405-408.
• 32 Endler G, Klimesch A, Sunder-Plassmann H. et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399-404.
• 33 Lopez-Cuenca AA, Tello-Montoliu A, Roldan V. et al. Prognostic value of mean platelet volume in patients with non-ST-elevation acute coronary syndrome. Angiology 2012; 63: 241-244.
• 34 Lippi G, Filippozzi L, Salvagno GL. et al. Increased mean platelet volume in patients with acute coronary syndromes. Arch Pathol Lab Med 2009; 133: 1441-1443.
• 35 Ranjith MP, Divya R, Mehta VK. et al. Significance of platelet volume indices and platelet count in ischaemic heart disease. J Clin Pathol 2009; 62: 830-833.
• 36 Huczek Z, Kochman J, Filipiak KJ. et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 46: 284-290.